Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience
April 2025
in “
The Journal of Dermatology
”
Studysummary This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study retrospectively examines the use of Janus kinase inhibitors (JAKi) in 26 patients with cutaneous T-cell lymphoma (CTCL) at a single cancer center from 2011 to 2024. Among these patients, 6 were treated with JAKi specifically for CTCL, with 4 receiving oral ruxolitinib and 2 receiving topical ruxolitinib. Notably, one patient on oral treatment achieved a complete response for 3 years, while another showed reduced lesion size over 1 year. Additionally, 9 patients received JAKi for graft versus host disease, with 5 experiencing CTCL relapse within a median of 8 weeks post-treatment. The findings suggest potential benefits of JAKi in CTCL management but highlight the need for further research to understand the safety and implications of JAKi use in CTCL patients.
